AKBA Akebia Therapeutics, Inc.
XNAS
10.40
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
What changed
Recent filings, trades and moves- Nov 5 Reported earnings before the open: EPS −$0.04 vs −$0.04 est. (−11.2%), revenue $37M · −37.7% vs ±32.4% implied
- Nov 16 8-K: Material agreement, Agreement terminated, New debt obligation, Unregistered share sale, Regulation FD disclosure, Other events
- IV rank fell from 54 to 30 over 5 sessions
- Oct 30 Short interest up 18% to 27.2M shares
- 52-Week Range
- $0.36 – $1.73
- YTD
- +570.97%
- IV Rank (30D)
- 30.5
- Straddle Price
- $4.47
- P/C Vol Ratio
- 0.64
- Market Cap
- $0.1B
- Open
- $0.40
- Day Range
- $0.40 – $0.43
- Volume
- 2,309,096
- Prev Close
- $0.41
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.12% |
| Beta vs SPY | 1.09 |
| Cost of Equity (CAPM) | 11.11% (VRP-adj) |
| WACC | 10.14% |
| Volatility Risk Premium | +124.7pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 5 years explicit + fade |
| Free Cash Flow (TTM) | $0.0B |
| Return on Equity (TTM) | -218.8% |
| Book / Price | 18.0% |
| Gross Margin (TTM) | 78.9% |
| FCF Margin (TTM) | 7.0% |
| Debt / Equity | 0.63 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $0.74 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $0.57 |
| Bollinger Width / SMA20 | 84.5% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $0.92 | 31% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $0.46 | 12% | median 6.3× · 8 peers |
| Peer P/S | $152.28 | 12% | median 213.8× · 5 peers |
| Market Anchor (SMA50) | $0.74 | 44% | stability 70% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 194
- List Date
- 2014-03-20
- CIK
- 0001517022
- Last Earnings
- Nov 5 before open · −37.7% vs ±32.4% expected
- Next Earnings
- ~Feb 25, 2027 (estimated)
- Headquarters
- Waltham, MA
- Homepage
- https://www.akebia.com
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, in…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 10.77% | -18.78% | 1.20% | 32.28% | 17.89% | -9.03% | 5.72% |
| Feb | 1.62% | 6.93% | 25.78% | -7.60% | -12.74% | -5.07% | 1.49% |
| Mar | 0.59% | -66.61% | -38.75% | 7.02% | 6.67% | 10.32% | -13.46% |
| Apr | -4.20% | -37.83% | 57.10% | -22.70% | 26.18% | -2.13% | 2.74% |
| May | 10.38% | -14.08% | 19.16% | -9.68% | 26.78% | -27.14% | 0.90% |
| Jun | 11.14% | 0.63% | -16.06% | -10.53% | 12.00% | 11.76% | 1.49% |
| Jul | -36.34% | 0.51% | 85.10% | 38.78% | 3.22% | 8.64% | 16.65% |
| Aug | 13.08% | -5.01% | -24.46% | 20.16% | -15.59% | -29.86% | -6.95% |
| Sep | -5.57% | -14.63% | -14.29% | -6.38% | -12.22% | -2.61% | -9.28% |
| Oct | 1.41% | -18.97% | -23.48% | 29.69% | -17.54% | -18.89% | -7.96% |
| Nov | -13.42% | -0.18% | 20.18% | 21.89% | -25.47% | -42.28%* | -6.55% |
| Dec | -12.06% | 97.54% | 15.89% | -10.80% | 6.62% | -- | 19.44% |
| Total | -30.16% | -79.70% | 56.47% | 79.87% | -1.47% | -73.62% | -8.10% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (6/10)
Key Drivers:
- Technical indicators suggest a weak trend with potential for further consolidation
- Recent news headlines highlight pipeline developments, which could drive future growth
- Risk metrics indicate above-average volatility, but options activity suggests market expectations are relatively conservative
Primary Risks:
- Continued market volatility could impact stock price performance
- Clinical trial outcomes and regulatory approvals will be crucial for the company's growth trajectory
Investment Thesis: AKBA presents a mixed bag of technical and fundamental signals. While recent news highlights pipeline developments, the technical indicators suggest a weak trend, and risk metrics indicate above-average volatility.
Recent News Sentiment Impact: The recent news headlines have had a positive impact on sentiment, with 3 out of 6 articles having a positive tone. This could lead to potential upside momentum in the short term.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Consolidation
- Medium-term (1-3 months): Weak uptrend
- Long-term (3-12 months): Bullish
Support/Resistance Levels:
- SMA 20: $0.92
- Upper Bollinger Band: $1.01
- Recent high: $1.03
Momentum Signals:
- RSI interpretation: Neutral (53.93)
- MACD signal: Bearish (-0.05 / Signal: 0.02 / Histogram: -0.05)
- Bollinger Bands position: Overbought (88.61)
Volume Analysis:
- Volume SMA 20: 8356354.65
- On-Balance Volume (OBV): 52183222.02
- Volume Rate of Change: -62.28%
News & Sentiment Analysis
Recent Headlines Summary:
- Pipeline developments and clinical trial updates have driven recent news headlines
Sentiment Assessment: Positive (3 out of 6 articles had a positive tone)
Catalyst Identification:
- Upcoming pipeline data releases and regulatory approvals will be crucial for the company's growth trajectory
Market Narrative:
- News sentiment aligns with technical signals, suggesting potential upside momentum in the short term
Risk & Volatility Assessment
Risk Metrics:
- Beta: 1.13 (vs SPY)
- Alpha: -0.98
- Correlation: 0.19
- Stock Volatility: 0.78
Options Market Signals:
- IV Rank: 73.5% (Medium)
- Current IV: 314.0%
- Expected Move: $0.53 (38 DTE), 7-DTE: $7.58
- Volume Flow: 92 calls vs 26 puts
- Open Interest: 1,996 calls vs 1,961 puts
- Put/Call Volume Ratio: 0.28 (Bullish sentiment)
Downside Protection:
- Support levels: SMA 20 ($0.92), recent low ($0.82)
- Risk management considerations: Stop-loss levels and position sizing considerations
Market Context & Positioning
Sector Performance:
- Relative strength vs sector/market: Neutral (0.19 correlation)
Institutional Activity:
- Volume patterns suggesting institutional interest: Higher-than-average volume flow, open interest in calls
Correlation Analysis:
- How stock moves relative to market: 0.78 volatility, 1.13 beta (amplification)
Relative Valuation:
- Position within trading range: Neutral (consolidation)
Key Levels & Action Items
Critical Price Levels:
- Support/resistance levels: SMA 20 ($0.92), recent high ($1.03)
- Breakout/Breakdown Levels: Upper Bollinger Band ($1.01), recent low ($0.82)
Time-Sensitive Catalysts:
- Upcoming pipeline data releases and regulatory approvals will be crucial for the company's growth trajectory
Risk Management:
- Stop-loss levels and position sizing considerations: $0.92 (SMA 20) and $0.82 (recent low)
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-25 | Pre-Market | 28.04% | 18.93% | 0.68x | Within |
| 2021-05-10 | Pre-Market | 16.03% | 7.05% | 0.44x | Within |
| 2021-08-05 | Pre-Market | 17.34% | 15.73% | 0.91x | Within |
| 2021-11-04 | Pre-Market | 7.49% | 8.98% | 1.20x | Exceeded |
| 2022-03-01 | Pre-Market | 20.83% | 0.46% | 0.02x | Within |
| 2022-05-09 | Pre-Market | 181.87% | 10.26% | 0.06x | Within |
| 2022-08-04 | Pre-Market | 174.14% | 4.99% | 0.03x | Within |
| 2023-03-09 | Pre-Market | 150.49% | 22.26% | 0.15x | Within |
| 2023-05-08 | Pre-Market | 129.36% | 2.75% | 0.02x | Within |
| 2024-01-08 | Pre-Market | 17.57% | 6.08% | 0.35x | Within |
| 2024-03-14 | Pre-Market | 14.89% | 2.84% | 0.19x | Within |
| 2024-05-09 | Pre-Market | 18.57% | 5.00% | 0.27x | Within |
| 2024-08-08 | Pre-Market | 22.52% | 7.21% | 0.32x | Within |
| 2024-11-07 | Pre-Market | 12.50% | 6.75% | 0.54x | Within |
| 2025-03-13 | Pre-Market | 15.54% | 12.44% | 0.80x | Within |
| 2025-05-08 | After-Close | 9.54% | 2.67% | 0.28x | Within |
| 2025-08-07 | Pre-Market | 36.33% | 20.48% | 0.56x | Within |
| 2025-11-10 | After-Close | 20.96% | 8.38% | 0.40x | Within |
| 2026-01-12 | After-Close | 12.50% | 1.43% | 0.11x | Within |
| 2026-02-26 | Pre-Market | 229.34% | 9.09% | 0.04x | Within |
| 2026-05-07 | After-Close | 21.19% | 1.69% | 0.08x | Within |
| 2026-08-05 | Pre-Market | 219.70% | 2.27% | 0.01x | Within |
| 2026-11-05 | Pre-Market | 32.39% | 38.75% | 1.20x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
AKBA Options Activity & IV Rank
AKBA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Options Flow · All expiries
ATM Options Pricing
Chain Summary
AKBA Implied Volatility
Loading implied volatility…
The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much AKBA actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Estimated net dealer gamma is at the 21st percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Loading the implied volatility surface…
Loading the implied volatility smile…
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
High volatility - stock moves more than market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $3.6M | #2248 of 3716 | +34.0% | 13F | |
| Citadel Hedge fund Ken Griffin | $2.0M | #2948 of 6285 | +23.6% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $1.7M | #2024 of 3151 | +53.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
AKBA Institutional Ownership (13F)
Filings for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $279.07K | 38.22% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $165.05K | 22.60% | 2026-09-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $114.54K | 15.69% | 2026-09-30 |
| 4 | Citadel Advisors LLC Custodian | $110.58K | 15.14% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $60.90K | 8.34% | 2026-09-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $304.72K | 51.97% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $190.61K | 32.51% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $41.40K | 7.06% | 2026-09-30 |
| 4 | Simplex Trading, LLC Custodian | $34.32K | 5.85% | 2026-09-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $15.27K | 2.60% | 2026-09-30 |
AKBA Insider Trading (Form 4)
Latest: 2026-08-10| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-10 | John P. Butler | CEO and President | Exer (M) | +350,000 | $0.63 | $220.5K | EDGAR |
| 2026-07-01 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | Sell (S) | −56,019 | $1.11 | -$62.2K | EDGAR |
| 2026-06-22 | Myles Wolf | Director | Award (A) | +35,700 | — | EDGAR | |
| 2026-06-22 | Michael W Rogers | Director | Award (A) | +35,700 | — | EDGAR | |
| 2026-06-22 | Leanne M Zumwalt | Director | Award (A) | +35,700 | — | EDGAR | |
| 2026-06-22 | Ron Frieson | Director | Award (A) | +35,700 | — | EDGAR | |
| 2026-06-22 | Cynthia Smith | Director | Award (A) | +35,700 | — | EDGAR | |
| 2026-06-22 | Adrian Adams | Director | Award (A) | +35,700 | — | EDGAR | |
| 2026-04-03 | Philip J. Vickers | Director | Grant (A) | +214,400 opt | — | EDGAR | |
| 2026-03-05 | John P. Butler | CEO and President | Buy (P) | +69,270 | $1.25 | $86.6K | EDGAR |
| 2026-02-04 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | Sell (S) | −34,951 | $1.39 | -$48.6K | EDGAR |
| 2026-02-04 | Steven Keith Burke | SVP, Chief Medical Officer | Sell (S) | −67,658 | $1.39 | -$94.0K | EDGAR |
| 2026-02-04 | Richard C Malabre | SVP, Chief Accounting Officer | Sell (S) | −49,524 | $1.39 | -$68.8K | EDGAR |
| 2026-02-04 | John P. Butler | CEO and President | Mixed Sell −341,305 · Grant +175,250 |
−166,055 | $1.40 | -$227.3K | EDGAR |
| 2026-02-04 | Nicholas Grund | Chief Commercial Officer | Sell (S) | −84,829 | $1.39 | -$117.9K | EDGAR |
AKBA Insider Holdings
13 insiders · @ $0.41| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | John P. Butler | CEO and President | 3,878,492 | $1.59M | -$999.1K | 37 | 2026-08-10 |
| 2 | Steven Keith Burke | SVP, Chief Medical Officer | 948,432 | $387.8K | -$364.1K | 22 | 2026-02-04 |
| 3 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | 616,616 | $252.1K | -$262.4K | 6 | 2026-07-01 |
| 4 | Carolyn M. Rucci | SVP, Chief Legal Officer | 588,378 | $240.6K | -$97.0K | 2 | 2026-02-04 |
| 5 | Nicholas Grund | Chief Commercial Officer | 561,750 | $229.7K | -$234.7K | 4 | 2026-02-04 |
| 6 | Richard C Malabre | SVP, Chief Accounting Officer | 299,390 | $122.4K | -$239.5K | 6 | 2026-02-04 |
| 7 | Adrian Adams | Director | 236,200 | $96.6K | $170.5K | 10 | 2026-06-22 |
| 8 | Michael W Rogers | Director | 197,429 | $80.7K | $0 | 9 | 2026-06-22 |
| 9 | Cynthia Smith | Director | 196,633 | $80.4K | -$2.5K | 10 | 2026-06-22 |
| 10 | Myles Wolf | Director | 169,081 | $69.1K | $0 | 7 | 2026-06-22 |
AKBA Board & Officers
As of SEC filings through Aug 10, 2026Directors 9
- John P. Butler · since Mar 19, 2014
- Cynthia Smith · since Aug 28, 2018
- Adrian Adams · since Dec 12, 2018
- Michael W Rogers · since Dec 12, 2018
- Steven C Gilman · since Dec 12, 2018
- Myles Wolf · since Apr 6, 2020
- Leanne M Zumwalt · since Feb 16, 2021
- Ron Frieson · since Nov 1, 2021
- Philip J. Vickers · since Apr 1, 2026
Officers 6
- John P. Butler · CEO and President · since Mar 19, 2014
- Erik Ostrowski · SVP, CFO, CBO & Treasurer · since Jun 24, 2024
- Steven Keith Burke · SVP, Chief Medical Officer · since Aug 1, 2019
- Nicholas Grund · Chief Commercial Officer · since Jan 8, 2024
- Richard C Malabre · SVP, Chief Accounting Officer · listed since Feb 2025
- Carolyn M. Rucci · SVP, Chief Legal Officer · since Jan 26, 2026
Changes in the last 10 years (30)
| Apr 1, 2026 | Philip J. Vickers became a director |
| Jan 26, 2026 | Carolyn M. Rucci became SVP, Chief Legal Officer |
| Feb 4, 2025 | Richard C Malabre listed as SVP, Chief Accounting Officer (previously Chief Accounting Officer) in SEC filings |
| Jun 24, 2024 | Erik Ostrowski became SVP, CFO, CBO & Treasurer |
| Mar 15, 2024 | The company announced the departure of Ellen Snow as SVP, CFO and Treasurer in an SEC filing |
| Jan 8, 2024 | Richard C Malabre became Chief Accounting Officer |
| Jan 8, 2024 | Nicholas Grund became Chief Commercial Officer |
| Oct 6, 2023 | The company announced the departure of Nicole R. Hadas as SVP, Chief Legal Officer in an SEC filing |
| Jul 10, 2023 | Ellen Snow became SVP, CFO and Treasurer |
| Jun 9, 2023 | The company announced the departure of David A Spellman as SVP, CFO and Treasurer in an SEC filing |
| Dec 14, 2022 | The company announced the departure of Violetta Cotreau as SVP, Chief Accounting Officer in an SEC filing |
| Nov 1, 2021 | Ron Frieson became a director |
| Apr 1, 2021 | Dell Faulkingham listed as SVP, Cco (previously Cco) in SEC filings |
| Feb 16, 2021 | Leanne M Zumwalt became a director |
| Jan 26, 2021 | Violetta Cotreau became SVP, Chief Accounting Officer |
| Jun 29, 2020 | David A Spellman became SVP, CFO and Treasurer |
| Apr 6, 2020 | Myles Wolf became a director |
| Mar 2, 2020 | Nicole R. Hadas listed as SVP, Chief Legal Officer (previously SVP, CLO & Secretary) in SEC filings |
| Mar 2, 2020 | Michel Dahan listed as SVP, Chief Operating Officer (previously SVP, Chief Business Officer) in SEC filings |
| Aug 1, 2019 | Steven Keith Burke became SVP, Chief Medical Officer |
| May 6, 2019 | Dell Faulkingham became Cco |
| Mar 5, 2019 | Nicole R. Hadas listed as SVP, CLO & Secretary (previously SVP, General Counsel, Sec.) in SEC filings |
| Dec 12, 2018 | Steven C Gilman became a director |
| Dec 12, 2018 | Michael W Rogers became a director |
| Dec 12, 2018 | Michael Thomas Heffernan became a director |
| Dec 12, 2018 | Mark J Enyedy became a director |
| Dec 12, 2018 | Jodie Pope Morrison became a director |
| Dec 12, 2018 | Adrian Adams became a director |
| Aug 28, 2018 | Cynthia Smith became a director |
| May 22, 2017 | Rita Jain became SVP, Chief Medical Officer |
- Prev
- 1
Not reported recently (16)
- Michel Dahan · Last reported as SVP, Chief Operating Officer in an SEC filing dated May 14, 2024
- Dell Faulkingham · Last reported as SVP, Cco in an SEC filing dated Mar 2, 2022
- Michael Thomas Heffernan · Last reported as a director in an SEC filing dated Jun 3, 2021
- Maxine Gowen · Last reported as a director in an SEC filing dated Jun 9, 2020
- Mark J Enyedy · Last reported as a director in an SEC filing dated Jun 9, 2020
- Jason Amello · Last reported as SVP, CFO & Treasurer in an SEC filing dated Mar 2, 2020
- Karen L Tubridy · Last reported as SVP, Chief Development Officer in an SEC filing dated Mar 2, 2020
- Scott A Canute · Last reported as a director in an SEC filing dated Jun 10, 2019
- Jodie Pope Morrison · Last reported as a director in an SEC filing dated Jun 10, 2019
- Rita Jain · Last reported as SVP, Chief Medical Officer in an SEC filing dated Apr 12, 2019
- Muneer A Satter · Last reported as a director in an SEC filing dated Jun 15, 2018
- Duane Nash · Last reported as a director in an SEC filing dated Jun 15, 2018
- Michael S Wyzga · Last reported as a director in an SEC filing dated Jun 15, 2018
- Michael D. Clayman · Last reported as a director in an SEC filing dated Jun 15, 2018
- Ronald C Renaud JR · Last reported as a director in an SEC filing dated Jun 15, 2018
- Bradley Maroni · Last reported as SVP and Chief Medical Officer in an SEC filing dated Feb 23, 2017
AKBA Proposed Insider Sales (Form 144)
Latest: 2026-06-29What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-06-29 | Ostrowski Erik | Officer | 56,019 | $62.2K | 2026-06-29 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2026-02-02 | Ostrowski Erik | Officer | 34,951 | $48.7K | 2026-02-02 | Morgan Stanley Smith Barney LLC | 10b5-1 | EDGAR |
| 2026-02-02 | Grund Nicholas | Officer | 84,829 | $118.3K | 2026-02-02 | Morgan Stanley Smith Barney LLC | 10b5-1 | EDGAR |
| 2026-02-02 | Burke Steven Keith | Officer | 67,658 | $94.3K | 2026-02-02 | Morgan Stanley Smith Barney LLC | 10b5-1 | EDGAR |
| 2026-02-02 | Butler John P. | Officer | 341,305 | $475.9K | 2026-02-02 | Morgan Stanley Smith Barney LLC | 10b5-1 | EDGAR |
| 2026-02-02 | Rucci Carolyn M. | Officer | 69,772 | $97.3K | 2026-02-02 | Morgan Stanley Smith Barney LLC | 10b5-1 | EDGAR |
| 2025-06-30 | Ostrowski Erik | Officer | 41,314 | $151.6K | 2025-06-30 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2025-03-03 | Burke Steven Keith | Officer | 7,144 | $13.1K | 2025-03-03 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2025-03-03 | Butler John P. | Officer, Director | 46,409 | $85.0K | 2025-03-03 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| 2025-02-03 | Grund Nicholas | Officer | 55,621 | $117.1K | 2025-02-03 | Morgan Stanley Smith Barney LLC | — | EDGAR |
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-16 | Material agreement · Agreement terminated · New debt obligation · Unregistered share sale · Regulation FD disclosure · Other events | EDGAR |
| 2026-11-05 | Earnings results | EDGAR |
| 2026-10-23 | Listing standards notice | EDGAR |
| 2026-10-14 | Director or officer change | EDGAR |
| 2026-08-05 | Earnings results | EDGAR |
| 2026-06-30 | Regulation FD disclosure · Other events | EDGAR |
| 2026-06-22 | Shareholder vote results | EDGAR |
| Filing Date | Accession | Link |
|---|
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $4.4M | — | 2026-10-31 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.00% | $2.7M | $75.0B | 2026-11-17 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $2.2M | — | 2026-10-31 |
| 4 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $1.1M | — | 2026-08-31 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $1.1M | — | 2026-10-31 |
| 6 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.01% | $893,023 | $13.5B | 2026-11-17 |
| 7 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.01% | $827,726 | $6.6B | 2026-11-17 |
| 8 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.02% | $594,870 | — | 2026-07-31 |
| 9 | VHT Vanguard Health Care ETF | Vanguard | 0.00% | $542,343 | — | 2026-10-31 |
| 10 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.03% | $313,557 | $1.2B | 2026-11-17 |
| 11 | SBIO ALPS Medical Breakthroughs ETF | Nport | 0.13% | $305,020 | — | 2026-08-31 |
| 12 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.01% | $250,192 | $4.1B | 2026-11-17 |
| 13 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $214,181 | — | 2026-08-31 |
| 14 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.01% | $174,900 | — | 2026-10-31 |
| 15 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $147,466 | $93.0B | 2026-11-17 |
| 16 | VFVA Vanguard U.S. Value Factor ETF | Vanguard | 0.01% | $141,284 | — | 2026-11-17 |
| 17 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.00% | $136,421 | $13.6B | 2026-11-17 |
| 18 | QQQS Invesco NASDAQ Future Gen 200 ETF | Invesco | 0.27% | $52,253 | — | 2026-11-17 |
| 19 | RSSL Global X Russell 2000 ETF | Global X | 0.00% | $49,556 | — | 2026-11-18 |
| 20 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $19,008 | $19.9B | 2026-11-17 |
| 21 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.00% | $17,622 | — | 2026-10-31 |
| 22 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $14,293 | — | 2026-10-31 |
| 23 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.00% | $5,944 | — | 2026-11-18 |
| 24 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $4,157 | — | 2026-11-18 |
| 25 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $2,743 | — | 2026-11-18 |
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $36.90M | $-14.35M | $-0.05 | $2.33M |
| Q2 '26 | 2026-06-30 | $49.13M | $-8.91M | $-0.03 | $3.52M |
| Q1 '26 | 2026-03-31 | $53.54M | $-9.05M | $-0.03 | $-21.21M |
| Q4 '25 | 2025-12-31 | $57.62M | $-12.24M | $-0.05 | $31.13M |
| Q3 '25 | 2025-09-30 | $58.77M | $540.00K | $0.00 | $28.11M |
| Q2 '25 | 2025-06-30 | $62.47M | $247.00K | — | $22.34M |
| Q1 '25 | 2025-03-31 | $57.34M | $6.11M | $0.03 | $-13.59M |
| Q4 '24 | 2024-12-31 | $46.50M | $-22.80M | $-0.11 | $-4.47M |
| Q3 '24 | 2024-09-30 | $37.43M | $-20.04M | $-0.10 | $-6.70M |
| Q2 '24 | 2024-06-30 | $43.65M | $-8.58M | $-0.04 | $-10.07M |
| Q1 '24 | 2024-03-31 | $32.61M | $-17.98M | $-0.09 | $-19.43M |
| Q4 '23 | 2023-12-31 | $56.20M | $614.00K | $0.00 | $-2.31M |
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
AKBA vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| APGE Apogee Therapeutics, Inc. Common Stock | $10.2B | — | — | +78.2% | — |
| CRNX Crinetics Pharmaceuticals, Inc. | $9.0B | — | +2928.4% | +81.8% | — |
| CGON CG Oncology, Inc. Common stock | $7.1B | — | +183.6% | +96.8% | 2 |
| ORKA Oruka Therapeutics, Inc. Common Stock | $6.5B | — | — | +245.3% | 40 |
| TVTX Travere Therapeutics, Inc. Common Stock | $4.8B | — | +49.4% | +22.8% | 31 |
| DNTH Dianthus Therapeutics, Inc. Common Stock | $4.7B | — | −11.7% | +115.0% | 83 |
| XENE Xenon Pharmaceuticals Inc | $3.7B | — | — | −15.1% | 53 |
| ACAD Acadia Pharmaceuticals Inc. | $3.1B | 8.5 | +14.8% | −32.8% | 12 |
| AKBA Akebia Therapeutics, Inc. | $114M | — | −12.4% | −72.6% | 30 |
| Peer median | $5.7B | 8.5 | +49.4% | +80.0% | 35 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.